Last reviewed · How we verify
NCT05417165
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Phase 2 trial testing Pneumococcal 20-valent Conjugate Vaccine in Chronic Lymphocytic Leukemia in 80 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Seema Bhat |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 29 September 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pneumococcal 20-valent Conjugate Vaccine (pneumococcal-20-valent-conjugate-vaccine) — full drug profile →
- Pneumococcal Polyvalent Vaccine — full drug profile →
Conditions studied
- Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
- Small Lymphocytic Lymphoma — all drugs for Small Lymphocytic Lymphoma →
Sponsor
Seema Bhat
Who can join
18 and older, any sex, with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vaccination. Current vaccination schedule for chronic lymphocytic leukemia patients is based on general recommendations in immunocompromised patients (initial vaccination with PCV13 followed by one dose of PSV23 after an interval of two months, followed by revaccination at 5 years). Giving patients frequent immunization as compared to 5 year immunization may result in higher protective titers in patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Vaccines for preventing infections in adults with haematological malignancies.
Zorger AM, Hirsch C, Baumann M, Feldmann M, et al · · 2025 · cited 4× · PMID 40396505 · DOI 10.1002/14651858.cd015530.pub2
Verify or expand the search:
- PubMed search for NCT05417165
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pneumococcal 20-valent Conjugate Vaccine
Trials testing the same drug.
- NCT05297578 — Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults · Phase 2 · completed
Other recruiting trials for Chronic Lymphocytic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
- NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
- NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
- NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting
Other Seema Bhat trials
Trials by the same sponsor.
- NCT06757647 — Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05417165 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seema Bhat
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417165.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing